Journal of Oncology / 2009 / Article / Tab 6

Review Article

Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers

Table 6

Selected clinical trials of sunitinib. GIST, gastrointestinal stromal tumor; PFS, progression free survival; OS, overall survival; PR, partial response; CR, complete response; TTP, time to progression; m RCC, metastatic renal cell carcinoma; QOL, quality of life.

MalignancyRegimenNumber of patientsResponse rateComments

RCCInterferon vs. Sunitinib [48]750 pts Previously untreated mRCCSunitinib: Median PFS (11 mo) ORR (31%) OS (26.4 mo), = 0.051 Interferon: Median PFS (5 mo) ORR (6%) OS (21.8 mo)Sunitinib provides superior QOL compared with IFN-α in mRCC patients.

GISTSunitinib vs. placebo [50]312 pts After progression or intolerance to imatinibSunitinib: TTP(6.3 mo) Placebo: TTP(1.5 month)Sunitinib significantly improved TTP with a 67% reduced risk of progression.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.